Clinical Trial Goal
To find out if a DC/AML vaccine, with or without the drug decitibine, given after allogeneic BMT is safe and works well to treat AML
You may be able to join this trial if you:
- Are 18 years old or older
- Have AML and are planning to get an allogeneic BMT
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
Doctors think that the DC/AML vaccine will teach your immune system how to find and kill AML cells.
Decitabine is a drug that blocks growth of cancer cells.
First, the clinical trial doctors will take a sample of your leukemia cells and use them to create the DC/AML vaccine in a lab.
About 2 months after your BMT, you’ll get:
Decitabine is a drug that blocks growth of cancer cells.
First, the clinical trial doctors will take a sample of your leukemia cells and use them to create the DC/AML vaccine in a lab.
About 2 months after your BMT, you’ll get:
- DC/AML vaccine – Given as a shot under the skin. You’ll get two doses 3 weeks apart. You may get a third dose if the clinical trial doctors think it’s best for your health
You may also get:
- Decitabine – Given as an intravenous (IV) infusion 1 time each day for 5 days
You’ll have biopsies to see how well treatment is working. The clinical trial doctors will check your health for up to 1 year.
The Food and Drug Administration (FDA) has approved decitibine to treat myelodysplastic syndrome (MDS). The FDA has not yet approved the DC/AML vaccine.
Watch a video about cancer treatment vaccines
Locations
Beth Israel Deaconess Medical CenterRECRUITING
Boston, Massachusetts
Emma Logan, BSN, 617-667-5984, eklogan@bidmc.harvard.edu
Dana Farber Cancer InstituteRECRUITING
Boston, Massachusetts
Robert J Soiffer, MD, Robert_soiffer@dfci.harvard.edu
Sponsors
collaborator: National Cancer Institute (NCI), collaborator: Dana-Farber Cancer Institute, lead: Beth Israel Deaconess Medical Center
